0001104659-19-005522.txt : 20190204 0001104659-19-005522.hdr.sgml : 20190204 20190204160729 ACCESSION NUMBER: 0001104659-19-005522 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190131 FILED AS OF DATE: 20190204 DATE AS OF CHANGE: 20190204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sender Gary CENTRAL INDEX KEY: 0001659085 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 19563746 MAIL ADDRESS: STREET 1: C/O SYNERGY PHARMACEUTICALS INC. STREET 2: 420 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2019-01-31 0 0001641640 Nabriva Therapeutics plc NBRV 0001659085 Sender Gary 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 Chief Financial Officer Stock Options 2019-01-31 4 A 0 138200 0.00 A 2029-01-31 Ordinary Shares 138200 138200 D Restricted Stock Units 2019-01-31 4 A 0 52500 0.00 A 2023-01-31 Ordinary Shares 52500 52500 D The exercise price is $1.90 per share. This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period. The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units. The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Robert Crotty, by power of attorney 2019-02-04